Rapamycin for Longevity: An Honest Assessment of the Evidence

Rapamycin is an immunosuppressant developed to prevent organ rejection in transplant recipients. It became one of the most discussed drugs in longevity medicine after a 2009 NIA study found that rapamycin extended median lifespan in mice by 9-14%, even when treatment started at the human equivalent of age 60. Since then, it has extended lifespan in every model organism tested. No other drug has a comparable track record across species.

How It Works: The mTOR Connection

Rapamycin inhibits mTOR (mechanistic target of rapamycin), a central regulator of cell growth and metabolism. When nutrients are abundant, mTOR is highly active and suppresses autophagy, cellular cleanup. Chronically high mTOR is associated with accelerated aging, cancer, and metabolic disease. Inhibiting mTOR mimics aspects of caloric restriction: it activates autophagy, reduces cellular senescence, and improves immune function.

The Human Evidence

We don't have longevity data in humans, that trial would take decades. A 2014 Novartis study showed low-dose rapamycin analogue treatment in elderly adults improved vaccine immune response by 20% and reduced infection rates. This matters because immune aging (immunosenescence) is a primary driver of age-related vulnerability. Multiple clinical trials are now underway examining rapamycin's effects on aging biomarkers and physical function.

The Real Risks

At transplant doses (daily, high dose), rapamycin carries significant risks: impaired wound healing, elevated blood lipids, mouth sores, and immune suppression. The off-label longevity protocol, typically 2-6 mg once weekly, uses a pulsed approach designed to allow the immune system to recover between doses. This appears to have a better safety profile, but it remains unstudied in large controlled trials in healthy adults.